Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Jianai Sun, Yi Xu, Huafeng Wang, Xiaolong Zheng, Wenjuan Yu, De Zhou, Chunmei Yang, Xinping Zhou, Liping Mao, Haitao Meng, Liangshun You, Min Yang, Hongyan Tong, Jie Jin, Wanzhuo Xie

Blood (2024) 144 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2024-197872

Published: 2024

Journal Articles

Improved Outcomes with Venetoclax in Combination with Mitoxantrone Liposome and Cytarabine for Myeloid Sarcoma By Preliminary Observations

Hongyan Tong, Yingwan Luo, Liping Huang, Xinping Zhou, Chen Mei

Blood (2024) 144 (Supplement 1): 6052.

https://doi.org/10.1182/blood-2024-212355

Published: 2024

Journal Articles

TP53 Mutations Distinguish a Class of Highly Homogenous Myeloid Neoplasms within MDS and AML in the Context of Complex Karyotype

Hongyan Tong, Ye Yang, Lingxu Jiang, Xinping Zhou, Liya Ma, Gaixiang Xu, Yudi Zhang, Wei Wang, Xiaozhen Liu, Huchu Yu

Blood (2024) 144 (Supplement 1): 6712.

https://doi.org/10.1182/blood-2024-207477

Published: 2024

Journal Articles

Decitabine Plus All- Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial

Blood (2024) 144 (Supplement 1): 663.

https://doi.org/10.1182/blood-2024-200433

Published: 2024

Journal Articles

High Expressions of Checkpoint Receptors in T Cells Subsets of Myelodysplastic Syndromes Patients with TP53 Mutations

Lingxu Jiang, Xin Huang, Xinping Zhou, Li Ye, Lu Wang, Chen Mei, Liya Ma, Gaixiang Xu, Chao Hu, Ziyang Zhou, Xiaozhen Liu, Yueyuan Han, Zheng Ge, Hongyan Tong

Blood (2023) 142 (Supplement 1): 4614.

https://doi.org/10.1182/blood-2023-182601

Published: 2023

Journal Articles

Analysis of Clinical Features, Prognostic Characteristics and Gene Mutations of the EB Subtype of Primary Myelodysplastic Syndrome Patients with Myelofibrosis

Gaixiang Xu, Wei Wang, Shuanghong Zhu, Kongfei Li, Xinping Zhou, Liya Ma, Li Ye, Chen Mei, Lu Wang, Lingxu Jiang, Haitao Meng, Wen-Juan Yu, Jie Jin, Hongyan Tong, Jian Huang

Blood (2023) 142 (Supplement 1): 6481.

https://doi.org/10.1182/blood-2023-184789

Published: 2023

Journal Articles

Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

Blood (2023) 142 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2023-184470

Published: 2023

Journal Articles

Small-Dose Trimethoprim-Sulfamethoxazole Prevents Pneumocystis Jiroveci Pneumonia in B-Cell Lymphoma Patients Receiving Chemotherapy: Analysis of a Randomized Controlled Clinical Trial

Blood (2023) 142 (Supplement 1): 6314.

https://doi.org/10.1182/blood-2023-189933

Published: 2023

Journal Articles

Safety and Efficacy of Selinexor Sequential Azacytidine in Newly Diagnosed Patients with Myelodysplastic Syndromes EB1 or EB2: A Single-Center, Single-Arm, Phase Ib/II Trial

Liya Ma, Wenli Yang, Xinping Zhou, Li Ye, Gaixiang Xu, Chao Hu, Yingwan Luo, Chunmei Yang, Zheng Ge, Hongyan Tong

Blood (2023) 142 (Supplement 1): 1856.

https://doi.org/10.1182/blood-2023-183101

Published: 2023

Journal Articles

EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes

Qi Zhang, Wei Lang, Lu Wang, Wenli Yang, Yingwan Luo, Shuanghong Zhu, Lingxu Jiang, Yuxia Wang, Chen Mei, Xinping Zhou, Yanling Ren, Liya Ma, Li Ye, Xingnong Ye, Gaixiang Xu, Jie Sun, Jie Jin, Hongyan Tong

Blood (2022) 140 (Supplement 1): 9767–9768.

https://doi.org/10.1182/blood-2022-165886

Published: 2022

Journal Articles

The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway

Lingxu Jiang, Xinping Zhou, Chao Hu, Chen Mei, Gaixiang Xu, Liya Ma, Yanling Ren, Li Ye, Lu Wang, Yingwan Luo, Jie Jin, Jie Sun, Hongyan Tong

Blood (2022) 140 (Supplement 1): 6894–6895.

https://doi.org/10.1182/blood-2022-165203

Published: 2022

Journal Articles

The ZR2-Minichop Study：Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Jianai Sun, Yi Xu, Min Yang, Huafeng Wang, Wenjuan Yu, Liangshun You, Haitao Meng, Chunmei Yang, Xinping Zhou, Li Li, De Zhou, Xiujing Ye, Hong-hu Zhu, Hongyan Tong, Jie Jin, Wanzhuo Xie

Blood (2022) 140 (Supplement 1): 3756.

https://doi.org/10.1182/blood-2022-158723

Published: 2022

Journal Articles

Analysis of Clinical Features, Prognostic Characteristics and Gene Mutations of Primary Myelodysplastic Syndrome Patients with Myelofibrosis

Gaixiang Xu, Shuanghong Zhu, Xinping Zhou, Kongfei Li, Lingxu Jiang, Hongyan Tong, Jie Jin

Blood (2022) 140 (Supplement 1): 9796–9797.

https://doi.org/10.1182/blood-2022-165344

Published: 2022

Journal Articles

15-Days Duration of Venetoclax Combined with Azacitidine in the Treatment of Relapsed/Refractory High-Risk Myelodysplastic Syndromes: A Retrospective Single-Center Study

Hongyan Tong, Chen Mei, Yanling Ren, Xinping Zhou, Yingwan Luo, Jie Jin

Blood (2022) 140 (Supplement 1): 12351–12352.

https://doi.org/10.1182/blood-2022-168938

Published: 2022

Journal Articles

Combination of Decitabine and ATRA in Newly Diagnosed Myelodysplastic Syndromes Subtype EB-Interim Analysis of a Multicenter, Randomized, Open-Label Trial

Xinping Zhou, Fanjun Meng, Yanjuan Lin, Zheng Ge, Yuemin Kuang, Lu Wang, Jin Zhang, Hai Cheng, Yan Gao, Yulu Tian, Li Huang, Jie Jin, Hongyan Tong

Blood (2021) 138 (Supplement 1): 539.

https://doi.org/10.1182/blood-2021-149326

Published: 2021

Journal Articles

Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial

Hongyan Tong, Docter, Xinping Zhou, Chen Mei, Jin Zhang, Ying Lu, Jianping Lan, MD, Shengyun Lin, Yuefeng Zhuang, Yuemin Kuang, Yanling Ren, Liya Ma, Juying Wei, Li Ye, Weilai Xu, Kongfei Li, Chenxi Lu, Jie Jin, MD PhD

Blood (2019) 134 (Supplement_1): 2594.

https://doi.org/10.1182/blood-2019-127675

Published: 2019

Journal Articles

The High NRF2 Expression Confers Chemotherapy Resistance through Upregulated DUSP1 in Myelodysplastic Syndromes

Peipei Lin, Yanling Ren, Xinping Zhou, Chen Mei, Chao Hu, Yingwan Luo, Yile Zhou, Xiaomei Yan, Gang Huang, PhD, Hongyan Tong, PhD

Blood (2017) 130 (Supplement 1): 2956.

https://doi.org/10.1182/blood.V130.Suppl_1.2956.2956

Published: 2017

NARROW

The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Improved Outcomes with Venetoclax in Combination with Mitoxantrone Liposome and Cytarabine for Myeloid Sarcoma By Preliminary Observations

TP53 Mutations Distinguish a Class of Highly Homogenous Myeloid Neoplasms within MDS and AML in the Context of Complex Karyotype

Decitabine Plus All- Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial

High Expressions of Checkpoint Receptors in T Cells Subsets of Myelodysplastic Syndromes Patients with TP53 Mutations

Analysis of Clinical Features, Prognostic Characteristics and Gene Mutations of the EB Subtype of Primary Myelodysplastic Syndrome Patients with Myelofibrosis

Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

Small-Dose Trimethoprim-Sulfamethoxazole Prevents Pneumocystis Jiroveci Pneumonia in B-Cell Lymphoma Patients Receiving Chemotherapy: Analysis of a Randomized Controlled Clinical Trial

Safety and Efficacy of Selinexor Sequential Azacytidine in Newly Diagnosed Patients with Myelodysplastic Syndromes EB1 or EB2: A Single-Center, Single-Arm, Phase Ib/II Trial

EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes

The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway

The ZR2-Minichop Study：Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Analysis of Clinical Features, Prognostic Characteristics and Gene Mutations of Primary Myelodysplastic Syndrome Patients with Myelofibrosis

15-Days Duration of Venetoclax Combined with Azacitidine in the Treatment of Relapsed/Refractory High-Risk Myelodysplastic Syndromes: A Retrospective Single-Center Study

Combination of Decitabine and ATRA in Newly Diagnosed Myelodysplastic Syndromes Subtype EB-Interim Analysis of a Multicenter, Randomized, Open-Label Trial

Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial

The High NRF2 Expression Confers Chemotherapy Resistance through Upregulated DUSP1 in Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only